1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Abbv-181: new trials by email Literature Review of Abbv-181 trials Research Report on Abbv-181
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382 Budigalimab, Placebo for Budigalimab, ABBV-382 - Human Immuno-deficiency Virus (HIV) Disease | Phase 2 | Terminated | AbbVie | 163 | 2023-10-12 | 2026-11-06 |
Disease (1)
AbbVie (1)
Belgium (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Poland (1) · Puerto Rico (1) · South Africa (1) · Spain (1) · United Kingdom (1) · United States (1)
2023 (1)